Research Topics
| G BakrisSummaryAffiliation: Rush University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Rosiglitazone reduces urinary albumin excretion in type II diabetesG Bakris
Rush University, Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
J Hum Hypertens 17:7-12. 2003..These findings suggest a potential beneficial effect of rosiglitazone in the treatment or prevention of renal and vascular complications of type II diabetes...- Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathyG L Bakris
Rush University Hypertension Center, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
Kidney Int 54:1283-9. 1998..Both angiotensin converting enzyme (ACE) inhibitors and the nondihydropyridine calcium antagonists, (non-DHPCAs) reduce both arterial pressure and proteinuria in those with diabetic nephropathy... - Microalbuminuria in diabetes: focus on cardiovascular and renal risk reductionGeorge L Bakris
Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
Curr Diab Rep 2:258-62. 2002..In this article we explore evidence for albuminuria being an integral component of the cardiometabolic syndrome and a risk factor for cardiovascular disease and stroke... - Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approachesGeorge L Bakris
Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 5:202-9. 2003..A fixed-dose combination approach appears as safe as the current conventional approaches... - ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidenceGeorge L Bakris
Department of Preventive Medicine, Rush Presbyterian St Lukes Medical Center, Chicago, IL 60612, USA
J Clin Hypertens (Greenwich) 4:420-3. 2002..This review critically evaluates the limited evidence in support of angiotensin-converting enzyme inhibitors as renal-protective agents in people with type 2 diabetes... - Optimal treatment of hypertension in African Americans. Reaching and maintaining target blood pressure goalsGeorge L Bakris
Departments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
Postgrad Med 112:73-4, 77-80, 83-4. 2002..This article describes current "best practice" guidance on appropriate treatment of high blood pressure in African Americans. Two patient scenarios offer insight into clinical strategies... - Pathogenesis and clinical physiology of hypertensionGeorge L Bakris
Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA
Cardiol Clin 20:195-206, v. 2002.... - Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular diseaseJay P Garg
Rush Presbyterian St Luke s Medical Center, Department of Preventive Medicine, Hypertensison Clinical Research Center, Chicago, IL 60612, USA
Vasc Med 7:35-43. 2002..Achieving such a goal with agents that also impact microalbuminuria will provide for a more complete cardiovascular risk reduction... - The evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocolsGeorge L Bakris
Deparments of Preventive Medicine and Internal Medicine, Rush Hypertension Clinical Research Center, Rush Presbyterian St Luke s Medical Center, 1700 W Van Buren St, Suite 470, Chicago, IL 60612, USA
Postgrad Med 113:35-40, 43-4, 50. 2003..He describes their backing in research findings and outlines practical antihypertensive and renoprotective therapies to curtail risks of nephropathy and cardiovascular disease in patients with diabetes... - Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetesJay Garg
Rush Medical Center, 1700 W Van Buren Street, Suite 470, Chicago, IL 60612, USA
Curr Hypertens Rep 4:185-90. 2002..5 mg/dL, should be placed on an ACE inhibitor for cardiovascular risk reduction. If nephropathy is present, the evidence would support an ARB for therapy in concert with a b-blocker for cardiovascular risk reduction and renoprotection... - The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trialGeorge L Bakris
Rush Hypertension Center, Rush Medical Center, Suite 470, 1700 W Van Buren, Chicago, IL 60612, USA
J Diabetes Complications 19:74-9. 2005..The GEMINI trial, therefore, is the first large randomized trial to assess whether utilizing a third-generation beta-blocker yields a favorable metabolic profile in the patient with Type 2 diabetes and hypertension... - A practical approach to achieving recommended blood pressure goals in diabetic patientsG L Bakris
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush University Hypertension Center, 1700 W Van Buren, Suite 470, Chicago, IL 60612, USA
Arch Intern Med 161:2661-7. 2001..A case study that applies these concepts in outpatient practice is included... - Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptorsG L Bakris
Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
Kidney Int 56:206-10. 1999..This lack of renoprotection may relate to nonspecific adrenergic stimulation by DA. The effect of select DA-1 receptor stimulation on renal hemodynamics following RCM administration has not been evaluated... - Hypertension in patients with diabetes. Why is aggressive treatment essential?G Bakris
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
Postgrad Med 107:53-6, 61-4. 2000..More aggressive treatment is needed to improve the prognosis for this over-expanding patient population... - ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study GroupG L Bakris
Hypertension Clinical Research Center, Rush University, Chicago, Illinois 60612, USA
Kidney Int 58:2084-92. 2000..No study has evaluated the comparative effects of an angiotensin-converting enzyme (ACE) inhibitor versus an angiotensin receptor blocker (ARB) on the changes in serum [K(+)] in people with renal insufficiency... - Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?G L Bakris
Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, Ill 60612, USA
Arch Intern Med 160:685-93. 2000..However, many physicians fail to use ACEIs or angiotensin receptor blockers in patients with renal insufficiency for fear that either serum creatinine or potassium levels will rise... 
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trialGeorge L Bakris
Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Lancet 375:1173-81. 2010..We assessed the effects of these drug combinations on progression of chronic kidney disease...- Choices and goals in the treatment of the diabetic hypertensive patientE Basta
Rush Medical Center, 1700 W. Van Buren Street, Suite 470, Chicago, IL 60612, USA
Curr Hypertens Rep 3:387-91. 2001..Combination therapy has been found to be very effective, and one arm should be an angiotensin converting enzyme inhibitor... - Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM studyG Bakris
Department of Preventive Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA
J Clin Hypertens (Greenwich) 3:16-21. 2001..Both drugs were well tolerated. (c)2001 by Le Jacq... - Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO studyI Lazich
Hypertensive Diseases Unit, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Diabetes Obes Metab 14:181-6. 2012..This study examines the effects of simvastatin combined with rosiglitazone on vascular inflammation, oxidant stress, ambulatory blood pressure (BP) and other atherosclerotic factors in patients with the metabolic syndrome... - Atlas vertebra realignment and achievement of arterial pressure goal in hypertensive patients: a pilot studyG Bakris
Department of Preventive Medicine, Rush University Hypertension Center, Chicago, IL, USA
J Hum Hypertens 21:347-52. 2007..5 beats per minute, placebo). No adverse effects were recorded. We conclude that restoration of Atlas alignment is associated with marked and sustained reductions in BP similar to the use of two-drug combination therapy... - Achieving blood pressure goals globally: five core actions for health-care professionals. A worldwide call to actionG Bakris
Department of Medicine, Hypertensive Diseases Center, University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
J Hum Hypertens 22:63-70. 2008..These actions should be pursued with vigour in accordance with current clinical guidelines, with the details of implementation adapted to the economic and cultural setting... - Beta-blockers in the treatment of hypertension: new data, new directionsMichael A Weber
State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
J Clin Hypertens (Greenwich) 10:234-8. 2008 - Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH studySverre E Kjeldsen
University of Michigan Health System, Ann Arbor, Michigan, USA
Blood Press 17:7-17. 2008..3%) and diabetic patients <130/80 mmHg (43.3%) at 12 months of follow-up than any other large outcomes trial. We have analyzed baseline predictors of BPs and BP control at 12 months... - Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studiesTimothy R Smith
Mercy Health Research, Washington University School of Medicine, St Louis, MO 63141, USA
J Clin Hypertens (Greenwich) 9:355-64. 2007..These findings were consistent with the primary efficacy analysis results from the overall study populations. Combination regimens were generally well tolerated by all patient subgroups... - Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular riskMichael A Weber
SUNY Downstate Medical College, 420 Lexington Avenue, Brooklyn, NY 10170, USA
Blood Press 16:13-9. 2007..It is noteworthy that the mean BMI of 31 in this cohort is clearly above the accepted diagnostic criterion of obesity and that 60% of patients are diabetic, possibly reflecting secular trends in clinical disease... - ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression?George L Bakris
J Clin Hypertens (Greenwich) 9:413-5. 2007 - Albuminuria and cardiovascular riskZvezdana Bogojevic
Rush University Medical Center, Chicago, IL 60612, USA
Heart Fail Clin 2:53-9. 2006 - Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetesGeorge L Bakris
Ann Intern Med 148:400-1. 2008 - Antihypertensive therapy in the presence of proteinuriaPantelis A Sarafidis
Hypertension Clinical Research Center, Department of Preventive Medicine, Rush University Medical Center, Chicago, IL, USA
Am J Kidney Dis 49:12-26. 2007.... - Efficacy of a once-daily formulation of carvedilol for the treatment of hypertensionMichael A Weber
State University of New York Downstate College of Medicine, Brooklyn, NY, USA
J Clin Hypertens (Greenwich) 8:840-9. 2006..Adverse events, including clinical chemistry values, were similar in the drug-treated and placebo groups. Carvedilol CR has a clinically meaningful defined dose-dependent antihypertensive effect that persists throughout a 24-hour period... - Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profileGeorge L Bakris
Hypertension Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois 60637, USA
Am J Cardiol 98:46L-52L. 2006..These will be the first head-to-head trials using carvedilol CR to determine whether the differing pharmacologic actions among beta-blockers result in varying effects on cardiovascular risk factors... - Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST])Rhonda Cooper-DeHoff
University of Florida College of Medicine, Gainesville, Florida, USA
Am J Cardiol 98:890-4. 2006.... - Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP)Peter A McCullough
Division of Cardiology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Arch Intern Med 167:1122-9. 2007..We hypothesized that each of these chronic kidney disease-related measures would have an independent relationship with CVD... - Body weight changes with beta-blocker use: results from GEMINIFranz H Messerli
St Luke s Roosevelt Hospital Center, New York City, NY 10019, USA
Am J Med 120:610-5. 2007.... - Hypertension awareness, treatment, and control in chronic kidney diseasePantelis A Sarafidis
Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
Am J Med 121:332-40. 2008..The objective of this study was to determine the state of blood pressure control in patients with chronic kidney disease... - Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyGeorge Bakris
Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois, USA
Kidney Int 74:364-9. 2008..We conclude that telmisartan is superior to losartan in reducing proteinuria in hypertensive patients with diabetic nephropathy, despite a similar reduction in blood pressure... - Comparative efficacy of two different beta-blockers on 24-hour blood pressure controlPantelis Sarafidis
Rush University Hypertension Clinical Research Center, Department of Preventive Medicine, Chicago, IL, USA
J Clin Hypertens (Greenwich) 10:112-8. 2008..It is possible that differences in outcome between atenolol-based and other therapies may be the result of inadequate dosing of atenolol, a medication that may not be effective for the entire 24-hour period... - Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?Matthew R Weir
Division of Nephrology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
J Clin Hypertens (Greenwich) 10:146-52. 2008..Studies are now under way to determine the relative benefits of an RAAS blocker/diuretic compared with an RAAS blocker/calcium channel blocker as initial therapy... 
Slowing nephropathy progression: focus on proteinuria reductionGeorge L Bakris
Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Clin J Am Soc Nephrol 3:S3-10. 2008..These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits...- Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blockerGeorge L Bakris
University of Chicago, Pritzker School of Medicine, Chicago, IL 60637, USA
J Clin Hypertens (Greenwich) 10:27-32. 2008..The combination of amlodipine and an angiotensin II receptor blocker is well tolerated, including in patients with stage 2 hypertension and the elderly... - Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI TrialJackson T Wright
Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
J Clin Hypertens (Greenwich) 9:842-9. 2007..The use of carvedilol compared with metoprolol did not effect glycemic control... - Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging studyHenry R Black
New York University School of Medicine, New York, NY 10016, USA
J Clin Hypertens (Greenwich) 9:760-9. 2007.... - Exceptional early blood pressure control rates: the ACCOMPLISH trialKenneth Jamerson
University of Michigan Health System, Division of Cardiovascular Medicine, Ann Arbor, Michigan 48106 0739, USA
Blood Press 16:80-6. 2007..At baseline, 97% of subjects were treated with anti-hypertensive medication at entry, but only 37% of participants had blood pressure (BP) control (<140/90 mmHg). Single-tablet combination therapy may improve control rates... - The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of HypertensionLuis Ruilope
Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
Blood Press 16:72-9. 2007.... - Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuriaGeorge L Bakris
Rush University Medical Center, Chicago, Illinois 60612, USA
J Hypertens 24:2047-55. 2006..To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control... - Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trialFranz H Messerli
St Luke s Roosevelt Hospital Center, New York, NY 10019, USA
J Clin Hypertens (Greenwich) 8:571-81; quiz 582-3. 2006..Concomitant administration of amlodipine and atorvastatin is an effective and well tolerated treatment for coexisting hypertension and dyslipidemia... - The importance of blood pressure control in the patient with diabetesGeorge L Bakris
Departments of Preventative and Internal Medicine, Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA
Am J Med 116:30S-38S. 2004..The new beta-blockers may play an important role in achieving blood pressure goals... - What have we learned from the current trials?Kevin C Abbott
Nephrology Service, Walter Reed Army Medical Center, 6900 Georgia Avenue, Building 2, Ward 48, Washington, DC 20307 5001, USA
Med Clin North Am 88:189-207. 2004..Based on the results of the AASK trial, the authors add the same for the use of ACE inhibitors in African Americans... - Diabetes and chronic kidney disease: tragedy and challengeDave Y Chua
Department of Preventive Medicine, Rush University Hypertension/Clinical Research Center, Rush Presbyterian/St. Luke's Medical Center, Chicago, IL 60612, USA
Blood Purif 22:130-5. 2004.... - A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trialCarl J Pepine
Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
JAMA 290:2805-16. 2003..CONCLUSION: The verapamil-trandolapril-based strategy was as clinically effective as the atenolol-hydrochlorothiazide-based strategy in hypertensive CAD patients... - Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blockerMichael A Weber
State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
J Clin Hypertens (Greenwich) 5:322-9. 2003..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients... - Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)Garabed Eknoyan
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Am J Kidney Dis 42:617-22. 2003 - Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL studyGeorge L Bakris
Department of Preventive Medicine, Rush Presbyterian St Luke s Medical Center, Rush Medical College, Chicago, IL 60612, USA
Arch Intern Med 163:1555-65. 2003..Clinical trials of nephropathy in people with type 2 diabetes mellitus have not examined the effects of systolic blood pressure (SBP) or pulse pressure (PP) on the time to end-stage renal disease (ESRD) or death... - The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportAram V Chobanian
Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
JAMA 289:2560-72. 2003..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount... - Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksJanice G Douglas
Case Western Reserve University, Department of Medicine, Room W-165, 10900 Euclid Ave, Cleveland, Ohio 44106, USA
Arch Intern Med 163:525-41. 2003 - Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcomeJames R Sowers
Departments of Medicine, Biochemistry, and Cell Biology, State University of New York Health Science Center, Brooklyn College of Medicine, Brooklyn, NY 11203, USA
Postgrad Med 112:24-6, 29-30, 33-4 passim. 2002..In this article, Drs Sowers, Ferdinand, Bakris, and Douglas examine the biologic, social, and genetic factors that contribute to these health disparities, the risk for which appears in early childhood... - Hypertension and diabetes: family physicians' pivotal roleGeorge L Bakris
Am Fam Physician 66:1151-2. 2002 - Evaluation and treatment of patients with systemic hypertensionJay Garg
Rush University Hypertension Center, Department of Preventive Medicine, Rush Presbyterian/St Luke's Medical Center, Chicago, IL 60612, USA
Circulation 105:2458-61. 2002 - Blood pressure control and nephroprotection in diabetesKevin Abbott
Walter Reed Army Hospital, Department of Medicine, Division of Nephrology, Bethesda, Maryland, USA
J Clin Pharmacol 44:431-8. 2004..Physicians need to work harder and educate patients on the importance of achieving these lower blood pressure guidelines... - Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) studyLuis M Ruilope
Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
J Hypertens 22:217-22. 2004.... - Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetesJames R Sowers
University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
J Clin Hypertens (Greenwich) 8:470-80. 2006..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy... - Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents in the treatment of hypertension?Panteleimon A Sarafidis
1st Department of Preventive Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Greece
J Clin Hypertens (Greenwich) 8:351-6; quiz 357-8. 2006.... - Differential effects of beta-blockers on albuminuria in patients with type 2 diabetesGeorge L Bakris
Rush University Medical Center, Chicago, IL 60612, USA
Hypertension 46:1309-15. 2005..These differences cannot be explained by effects on blood pressure or alpha1-antagonism but may relate to antioxidant properties of carvedilol... - The effect of ruboxistaurin on nephropathy in type 2 diabetesKatherine R Tuttle
Research Department, The Heart Institute and Sacred Heart Medical Center, Spokane, WA 99204 2340, USA
Diabetes Care 28:2686-90. 2005..Ruboxistaurin selectively inhibits protein kinase C-beta and ameliorates kidney disease in animal models of diabetes. The purpose of this study was to evaluate the effects of ruboxistaurin on diabetic nephropathy in humans... - Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetesNathaniel Winer
SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
Prev Cardiol 8:87-92. 2005..05). No significant change in small-vessel compliance was observed with either treatment. Greater improvement in large-vessel compliance with combination therapy was independent of BP lowering... - The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertensionJanice Lea
Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA
Arch Intern Med 165:947-53. 2005..CONCLUSIONS: The change in the level of proteinuria is a predictor of subsequent progression of hypertensive kidney disease at a given GFR. A prospective trial is needed to confirm this observation... - Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trialGeorge L Bakris
Department of Preventive Medicine, Rush University Medical Center, Chicago, Ill, USA
JAMA 292:2227-36. 2004..The effects of the 2 beta-blockers on clinical outcomes need to be compared in long-term clinical trials... - Slowing the progression of diabetic nephropathy and its cardiovascular consequencesPeter A McCullough
Division of Nutritional and Preventive Medicine, William Beaumont Hospital, Beaumont Health Center, 4949 Coolidge, Royal Oak, MI 48073, USA
Am Heart J 148:243-51. 2004..The goal of an ideal clinical trial would be ESRD prevention; however, pragmatic objectives such as a greater understanding of therapeutic toxicities should also be explored in this population... - The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapyJonathan C Fox
Merck Research Laboratories, BLX-21, P.O. Box 4, West Point, PA 19486, USA
J Clin Hypertens (Greenwich) 6:437-42; quiz 443-4. 2004..The use of two medications will achieve goal BP in more patients than monotherapy. This observation is important in treatment of high-risk patients with diabetes... - Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapySteven G Chrysant
Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, Oklahoma 73132, USA
Am J Hypertens 17:590-6. 2004.... - The role of calcium antagonists in chronic kidney diseaseCasey N Gashti
Rush University Hypertension/Clinical Research Centre, Department of Preventive Medicine, Rush Presbyterian/St Luke's Medical Centre, Chicago, Illinois 60612, USA
Curr Opin Nephrol Hypertens 13:155-61. 2004.... - Management of hypertension in the cardiometabolic syndrome and diabetesNitin Khosla
Rush University Hypertension Center, Rush University Medical Center, 1700 W. Van Buren Street, Suite 470, Chicago, IL 60612, USA
Curr Diab Rep 4:199-205. 2004..Thus, treating the cardiometabolic syndrome requires an aggressive approach with a focus on both lifestyle modification and pharmacologic intervention... - Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment optionsDomenic A Sica
Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298 1060, USA
J Clin Hypertens (Greenwich) 4:52-7. 2002..An evidence-based therapeutic approach derived from these trials would argue for ARBs to be the foundation of therapy in the patient with type 2 diabetes and nephropathy...